The hypoglycemic effect of ciglitazone in obese, hyperglycemic animal models.
D000273:Adipose Tissue / Q000378:metabolism; D002001:Adipose Tissue, Brown / Q000378:metabolism; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D004195:Disease Models, Animal; D006019:Glycolysis; D006943:Hyperglycemia / Q000150:complications / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008817:Mice, Mutant Strains; D008820:Mice, Obese; D008928:Mitochondria / Q000378:metabolism; D009765:Obesity / Q000150:complications / Q000188:drug therapy*; D010101:Oxygen Consumption; D011972:Receptor, Insulin / Q000378:metabolism; D013844:Thiazoles / Q000627:therapeutic use*; D045162:Thiazolidinediones
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D013844:Thiazoles; D045162:Thiazolidinediones; D011972:Receptor, Insulin; C039671:ciglitazone